Adverse effects of the common treatments for polycystic ovary syndrome: A systematic review and meta-analysis

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 12, 2013, Pages 4646-4654

  Domecq, Juan Pablo ^a,b,f   Prutsky, Gabriela ^a,b,g   Mullan, Rebecca J ^a,c   Sundaresh, Vishnu ^a,h   Wang, Amy T ^a   Erwin, Patricia J ^a   Welt, Corrine ^d   Ehrmann, David ^e   Montori, Victor M ^a,b   Murad, Mohammad Hassan ^a  

^a MAYO CLINIC   (United States)

^b Unidad de Conocimiento y Evidencia   (Peru)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f HENRY FORD HOSPITAL   (United States)

^g WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Louisiana State University School of Medicine Shreveport   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; CHLORMADINONE ACETATE; CLOMIFENE CITRATE; DROSPIRENONE; ETHINYLESTRADIOL; FLUTAMIDE; METFORMIN; ORAL CONTRACEPTIVE AGENT;

CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; LACTIC ACIDOSIS; LIVER INJURY; LIVER TOXICITY; LOW DRUG DOSE; META ANALYSIS; OBSERVATIONAL STUDY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; WEIGHT GAIN;

ANDROGEN ANTAGONISTS; CONTRACEPTIVES, ORAL; EVIDENCE-BASED MEDICINE; FEMALE; FLUTAMIDE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; POLYCYSTIC OVARY SYNDROME; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 84889863920     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2374     Document Type: Review

References (63)

1. Asunción M, Calvo RM, San Millán JL, Sancho J, Avila S, Escobar-Morreale HF.Aprospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000;85:2434-2438.
2. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: A prospective study. J Clin Endocrinol Metab. 1998;83:3078-3082.
3. Balen A. Polycystic ovary syndrome and cancer. Hum Reprod Update. 2001;7:522-525.
4. Fearnley EJ, Marquart L, Spurdle AB, Weinstein P, Webb PM. Polycystic ovary syndrome increases the risk of endometrial cancer in women aged less than 50 years: An Australian case-control study. Cancer Causes Control. 2010;21:2303-2308.
5. Ehrmann DA. Polycystic ovary syndrome.NEngl J Med. 2005;352: 1223-1236.
6. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989;38:1165-1174.
7. Toprak S, Yönem A, Cakir B, Güler S, Azal O, Ozata M, Corakçi A. Insulin resistance in nonobese patients with polycystic ovary syndrome. Horm Res. 2001;55:65-70.
8. Leibel NI, Baumann EE, Kocherginsky M, Rosenfield RL. Relationship of adolescent polycystic ovary syndrome to parental metabolic syndrome. J Clin Endocrinol Metab. 2006;91:1275-1283.
9. Coviello AD, Legro RS, Dunaif A. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab. 2006;91:492-497.
10. Ovalle F, Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril. 2002;77:1095-1105.
11. Moran LJ, Pasquali R, Teede HJ, Hoeger KM, Norman RJ. Treatment of obesity in polycystic ovary syndrome: A position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertil Steril. 2009;92:1966-1982.
12. Martin KA, Chang RJ, EhrmannDA,et al. Evaluation and treatment of hirsutism in premenopausal women: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:1105-1120.
13. Stang M, Wysowski DK, Butler-Jones D. Incidence of lactic acidosis in metformin users. Diabetes Care. 1999;22:925-927.
14. Lopez LM, Edelman A, Chen-Mok M, Trussell J, Helmerhorst FM. Progestin-only contraceptives: Effects on weight. Cochrane Database Syst Rev. 2011:CD008815.
15. Gruber DM, Huber JC. [Mortality associated with oral contraceptive use: 25-year follow-up of a cohort of 46,000 women from Royal College of General Practitioners's Oral Contraception Study. Analysis and comment on the BMJ study of the long-term risk of using oral contraceptives]. Gynakol Geburtshilfliche Rundsch. 1999;39: 231-232.
16. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ. 2001;323:131-134.
17. Andrade RJ, Lucena MI, Fernandez MC, et al. Fulminant liver failure associated with flutamide therapy for hirsutism. Lancet. 1999; 353:983.
18. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
19. Altman DG, Bland JM. Interaction revisited: The difference between two estimates. BMJ. 2003;326:219.
20. Legro RS, Barnhart HX, Schlaff WD, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med. 2007;356:551-566.
21. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010:CD002967.
22. Dikensoy E, Balat O, Pence S, Akcali C, Cicek H. The risk of hepatotoxicity during long-term and low-dose flutamide treatment in hirsutism. Arch Gynecol Obstet. 2009;279:321-327.
23. Ibáñez L, Jaramillo A, Ferrer A, de Zegher F. Absence of hepatotoxicity after long-term, low-dose flutamide in hyperandrogenic girls and young women. Human Reprod. 2005;20:1833-1836.
24. Brahm J, Brahm M, Segovia R, et al. Acute and fulminant hepatitis induced by flutamide: Case series report and review of the literature. Ann Hepatol. 2011;10:93-98.
25. García Cortés M, Andrade RJ, Lucena MI, et al. Flutamide-induced hepatotoxicity: Report of a case series. Rev Esp Enferm Dig. 2001; 93:423-432.
26. Venous thromboembolic disease and combined oral contraceptives: Results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1995;346:1575-1582.
27. Dinger JC, Heinemann LA, Kühl-Habich D. The safety of a drospirenone- containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception. 2007;75:344-354.
28. Lidegaard Ø, Løkkegaard E, Jensen A, Skovlund CW, Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med. 2012;366:2257-2266.
29. Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: A meta-analysis. Circulation. 2008;117:93-102.
30. Hannaford PC, Iversen L, Macfarlane TV, ElliottAM,Angus V, Lee AJ. Mortality among contraceptive pill users: Cohort evidence from Royal College of General Practitioners' Oral Contraception Study. BMJ. 2010;340:c927.
31. Chan WS, Ray J, Wai EK, et al. Risk of stroke in women exposed to low-dose oral contraceptives: A critical evaluation of the evidence. Arch Intern Med. 2004;164:741-747.
32. Hannaford PC, Selvaraj S, Elliott AM, Angus V, Iversen L, Lee AJ. Cancer risk among users of oral contraceptives: Cohort data from the Royal College of General Practitioner's oral contraception study. BMJ. 2007;335:651.
33. Gallo MF, Lopez LM, Grimes DA, Schulz KF, Helmerhorst FM. Combination contraceptives: Effects on weight. Cochrane Database Syst Rev. 2011;9:CD003987.
34. Lindh I, Ellström AA, Milsom I. The long-term influence of combined oral contraceptives on body weight. Hum Reprod. 2011;26: 1917-1924.
35. Rosendaal FR, Van Hylckama Vlieg A, Tanis BC, Helmerhorst FM. Estrogens, progestogens and thrombosis. J Thromb Haemost. 2003; 1:1371-1380.
36. Dentali F, Crowther M, Ageno W. Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: A metaanalysis. Blood. 2006;107:2766-2773.
37. Carmina E. Oral contraceptives and cardiovascular risk in women with polycystic ovary syndrome. J Endocrinol Invest. 2013;36:358-363.
38. Baillargeon JP, Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Nestler JE. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril. 2004;82:893-902.
39. Begum MR, Khanam NN, Quadir E, et al. Prevention of gestational diabetes mellitus by continuing metformin therapy throughout pregnancy inwomenwith polycystic ovary syndrome. J Obstet Gynaecol Res. 2009;35:282-286.
40. Gambineri A, Pelusi C, Genghini S, et al. Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol. 2004;60: 241-249.
41. Gambineri A, Patton L, Vaccina A, et al. Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: A randomized, 12-month, placebo-controlled study. J Clin Endocrinol Metab. 2006;91:3970-3980.
42. Hoeger KM,Kochman L,Wixom N, Craig K, Miller RK,Guzick DS. A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: A pilot study. Fertil Steril. 2004; 82:421-429.
43. Hoeger K, Davidson K, Kochman L, Cherry T, Kopin L, Guzick DS. The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J Clin Endocrinol Metab. 2008;93:4299-4306.
44. Kelly CJG, Gordon D. The effect of metformin on hirsutism in polycystic ovary syndrome. Eur. J. Endocrinol. 2002;147:217-221.
45. Ladson G, Dodson WC, Sweet SD, et al. The effects of metformin with lifestyle therapy in polycystic ovary syndrome: A randomized double-blind study. Fertil Steril. 2011;95(3):1059-1066.e1-e7.
46. Maciel GA, Soares Júnior JM, Alves da Motta EL, Abi Haidar M, de Lima GR, Baracat EC. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertil Steril. 2004;81:355-360.
47. Naka KK, Kalantaridou SN, Kravariti M, et al. Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: A prospective randomized study. Fertil Steril. 2011;95:203-209.
48. Onalan G, Goktolga U, Ceyhan T, Bagis T, Onalan R, Pabuçcu R. Predictive value of glucose-insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic? Eur J Obstet Gynecol Reprod Biol. 2005; 123:204-211.
49. Palomba S, Falbo A, Russo T, et al. Insulin sensitivity after metformin suspension in normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2007;92:3128-3135.
50. Pasquali R, Gambineri A, Biscotti D, et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab. 2000;85:2767-2774.
51. Rezvanian H, Adibi N, Siavash M, Kachuei A, Shojaee-Moradie F, Asilian A. Increased insulin sensitivity by metformin enhances intense- pulsed-light-assisted hair removal in patients with polycystic ovary syndrome. Dermatology. 2009;218:231-236.
52. Romualdi D, Giuliani M, Cristello F, et al. Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal- weight normoinsulinemic women with polycystic ovary syndrome: A randomized double-blind placebo-controlled clinical trial. Fertil Steril. 2010;93:2303-2310.
53. Tang T, Glanville J, Hayden CJ, White D, Barth JH, Balen AH. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome.Arandomized, placebo-controlled, double-blind multicentre study. Hum Reprod. 2006;21:80-89.
54. Trolle B, Flyvbjerg A, Kesmodel U, Lauszus FF. Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: A randomized, double-blinded, placebo-controlled crossover trial. Hum Reprod. 2007;22:2967-2973.
55. Trolle B, Lauszus FF, Frystyk J, Flyvbjerg A. Adiponectin levels in women with polycystic ovary syndrome: Impact of metformin treatment in a randomized controlled study. Fertil Steril. 2010;94:2234-2238.
56. Fougner KJ, Vanky E, Carlsen SM. Metformin has no major effects on glucose homeostasis in pregnant women with PCOS: Results of a randomized double-blind study. Scand J Clin Lab Invest. 2008;68: 771-776.
57. Vanky E, Salvesen KA, Heimstad R, Fougner KJ, Romundstad P, Carlsen SM. Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: Results of a randomized study. Hum Reprod. 2004;19: 1734-1740.
58. Salvesen KA, Vanky E, Carlsen SM. Metformin treatment in pregnant women with polycystic ovary syndrome-is reduced complication rate mediated by changes in the uteroplacental circulation? Ultrasound Obstet Gynecol. 2007;29:433-437.
59. Nawaz FH, Khalid R, Naru T, Rizvi J. Does continuous use of metformin throughout pregnancy improve pregnancy outcomes in women with polycystic ovarian syndrome? J Obstetr Gynaecol Res. 2008;34:832-837.
60. Vanky E, Stridsklev S, Heimstad R, et al. Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: A randomized, controlled multicenter study. J Clin Endocrinol Metab. 2010;95:E448-455.
61. Gambineri A, Pagotto U, Tschöp M, et al. Anti-androgen treatment increases circulating ghrelin levels in obese women with polycystic ovary syndrome. J Endocrinol Invest. 2003;26:629-634.
62. Uras R, Orrù M, Pani F, et al. Endocrinological, metabolic and clinical features of treatment with oral contraceptive formulation containing ethinylestradiol plus chlormadinone acetate in nonobese women with polycystic ovary syndrome. Contraception. 2010;82: 131-138.
63. Ibáñez L, de Zegher F. Low-dose combination of flutamide, metformin and an oral contraceptive for non-obese, young women with polycystic ovary syndrome. Hum Reprod. 2003;18:57-60.